Connection
Co-Authors
This is a "connection" page, showing publications co-authored by Marc Bonaca and Connie Hess.
|
|
Connection Strength |
|
|
|
|
|
12.643 |
|
|
|
-
Hess CN, Hsia J, Carroll IA, Nehler MR, Ruf W, Morrow DA, Nicolau JC, Berwanger O, Szarek M, Capell WH, Johri S, Pursley MS, Gupta R, Meehan PS, Franchi F, Effron MB, Marshall D, Graybill CA, Huebler SP, Keuer T, Bristow MR, Bonaca MP. Novel Tissue Factor Inhibition for Thromboprophylaxis in COVID-19: Primary Results of the ASPEN-COVID-19 Trial. Arterioscler Thromb Vasc Biol. 2023 08; 43(8):1572-1582.
Score: 0.904
-
Hess CN, Bonaca MP. Guideline-Directed Medical Therapy in?PAD: Time to Step on the Gas. JACC Cardiovasc Interv. 2023 02 13; 16(3):344-346.
Score: 0.881
-
Hess CN, Bonaca MP. Risk of remnants and remnant risk in peripheral artery disease. Eur Heart J. 2022 09 07; 43(34):3270-3272.
Score: 0.855
-
Hess CN, Szarek M, Anand SS, Bauersachs RM, Patel MR, Debus ES, Nehler MR, Capell WH, Beckman JA, Piazza G, Henkin S, Bura-Rivi?re A, Lawall H, Roztocil K, Hsia J, Muehlhofer E, Berkowitz SD, Haskell LP, Bonaca MP. Rivaroxaban and Risk of Venous Thromboembolism in Patients With Symptomatic Peripheral Artery Disease After Lower Extremity Revascularization. JAMA Netw Open. 2022 06 01; 5(6):e2215580.
Score: 0.839
-
Hess CN, Capell WH, Bristow MR, Ruf W, Szarek M, Morrow DA, Nicolau JC, Graybill CA, Marshall D, Hsia J, Bonaca MP. Rationale and design of a study to assess the safety and efficacy of rNAPc2 in COVID-19: the Phase 2b ASPEN-COVID-19 trial. Am Heart J. 2022 04; 246:136-143.
Score: 0.816
-
Hess CN, Patel MR, Bauersachs RM, Anand SS, Debus ES, Nehler MR, Fanelli F, Yeh RW, Secemsky EA, Beckman JA, Mauri L, Govsyeyev N, Capell WH, Brackin T, Berkowitz SD, Muehlhofer E, Haskell LP, Hiatt WR, Bonaca MP. Safety and Effectiveness of Paclitaxel Drug-Coated Devices in Peripheral Artery?Revascularization: Insights From VOYAGER PAD. J Am Coll Cardiol. 2021 11 02; 78(18):1768-1778.
Score: 0.806
-
Hess CN, Debus ES, Nehler MR, Anand SS, Patel MR, Szarek M, Capell WH, Hsia J, Beckman JA, Brodmann M, Diaz R, Habertheuer P, Leeper NJ, Powell RJ, Sillesen H, Muehlhofer E, Berkowitz SD, Haskell LP, Bauersachs RM, Bonaca MP. Reduction in Acute Limb Ischemia With Rivaroxaban Versus Placebo in Peripheral Artery Disease After Lower Extremity Revascularization: Insights From VOYAGER PAD. Circulation. 2021 12 07; 144(23):1831-1841.
Score: 0.803
-
Hess CN, Cannon CP, Beckman JA, Goodney PP, Patel MR, Hiatt WR, Mues KE, Orroth KK, Shannon E, Bonaca MP. Effectiveness of Blood Lipid Management in Patients With Peripheral Artery Disease. J Am Coll Cardiol. 2021 06 22; 77(24):3016-3027.
Score: 0.786
-
Hess CN, Fu JW, Gundrum J, Allen LaPointe NM, Wang TY, Rogers RK, Hiatt WR, Bonaca MP. Diabetes Mellitus and Risk Stratification After Peripheral Artery Revascularization. J Am Coll Cardiol. 2021 06 08; 77(22):2867-2869.
Score: 0.784
-
Hess CN, Bonaca MP. Contemporary Review of Antithrombotic Therapy in Peripheral Artery Disease. Circ Cardiovasc Interv. 2020 10; 13(10):e009584.
Score: 0.749
-
Bonaca MP, Hess CN. ASCVD Risk and Statin Use in PAD: Implementing a New Approach to an Old Problem. J Am Coll Cardiol. 2020 07 21; 76(3):265-267.
Score: 0.738
-
Canonico ME, Piccolo R, Avvedimento M, Leone A, Esposito S, Franzone A, Giugliano G, Gargiulo G, Hess CN, Berkowitz SD, Hsia J, Cirillo P, Esposito G, Bonaca MP. Antithrombotic Therapy in Peripheral Artery Disease: Current Evidence and Future Directions. J Cardiovasc Dev Dis. 2023 Apr 10; 10(4).
Score: 0.223
-
Canonico ME, Hsia J, Hess CN, Bonaca MP. Sex differences in guideline-directed medical therapy in 2021-22 among patients with peripheral artery disease. Vasc Med. 2023 06; 28(3):233-235.
Score: 0.221
-
Govsyeyev N, Nehler M, Conte MS, Debus S, Chung J, Dorigo W, Gudz I, Krievins D, Mills J, Moll F, Norgren L, Piffaretti G, Powell R, Szalay D, Sillesen H, Wohlauer M, Szarek M, Bauersachs RM, Anand SS, Patel MR, Capell WH, Jaeger N, Hess CN, Muehlhofer E, Haskell LP, Berkowitz SD, Bonaca MP. Rivaroxaban in patients with symptomatic peripheral artery disease after lower extremity bypass surgery with venous and prosthetic conduits. J Vasc Surg. 2023 04; 77(4):1107-1118.e2.
Score: 0.217
-
Bonaca MP, Hess C, Beckman JA. Telmisartan and Walking Performance in Peripheral Artery Disease. JAMA. 2022 10 04; 328(13):1302-1303.
Score: 0.215
-
Hess CN, Baumgartner I, Anand SS, Nehler MR, Patel MR, Debus ES, Szarek M, Capell W, Muehlhofer E, Berkowitz SD, Haskell LP, Bauersachs RM, Bonaca MP, Hsia J. Sex-Based Differences in Outcomes Following Peripheral Artery Revascularization: Insights From VOYAGER PAD. J Am Heart Assoc. 2022 06 21; 11(12):e024655.
Score: 0.210
-
Szarek M, Hess C, Patel MR, Jones WS, Berger JS, Baumgartner I, Katona B, Mahaffey KW, Norgren L, Blomster J, Rockhold FW, Hsia J, Fowkes FGR, Bonaca MP. Total Cardiovascular and Limb Events and the Impact of Polyvascular Disease in Chronic Symptomatic Peripheral Artery Disease. J Am Heart Assoc. 2022 06 07; 11(11):e025504.
Score: 0.210
-
Hogan SE, Nehler MR, Anand S, Patel MR, Debus S, Jackson MT, Buchanan C, King RW, Hess C, Muehlhofer E, Haskell LP, Bauersachs RM, Berkowitz SD, Hsia J, Bonaca MP. Improvement in walking impairment following surgical and endovascular revascularization: Insights from VOYAGER PAD. Vasc Med. 2022 08; 27(4):343-349.
Score: 0.208
-
Berkowitz SD, Bauersachs RM, Szarek M, Nehler MR, Debus ES, Patel MR, Anand SS, Capell WH, Hess CN, Hsia J, Leeper NJ, Brasil D, M?ty?s L, Diaz R, Brodmann M, Muehlhofer E, Haskell LP, Bonaca MP. Prevention of arterial and venous thrombotic events in symptomatic peripheral arterial disease patients after lower extremity revascularization in the VOYAGER PAD trial: Dual anticoagulant/antiplatelet regimen vs antiplatelet therapy alone. J Thromb Haemost. 2022 05; 20(5):1193-1205.
Score: 0.206
-
Morrison JT, Govsyeyev N, Hess CN, Bonaca MP. Vorapaxar for Prevention of Major Adverse Cardiovascular and Limb Events in Peripheral Artery Disease. J Cardiovasc Pharmacol Ther. 2022 Jan-Dec; 27:10742484211056115.
Score: 0.204
-
Rogers RK, Reece TB, Bonaca MP, Hess CN. Acute Aortic Syndromes. Cardiol Clin. 2021 Nov; 39(4):495-503.
Score: 0.202
-
Krantz MJ, Debus SE, Hsia J, Patel MR, Anand SS, Nehler MR, Hess CN, Capell WH, Bracken T, Szarek M, M?ty?s L, Krievins DK, Nault P, Stefanov S, Haskell LP, Berkowitz SD, Muehlhofer E, Hiatt WR, Bauersachs RM, Bonaca MP. Low-dose rivaroxaban plus aspirin in older patients with peripheral artery disease undergoing acute limb revascularization: insights from the VOYAGER PAD trial. Eur Heart J. 2021 10 14; 42(39):4040-4048.
Score: 0.201
-
Debus ES, Nehler MR, Govsyeyev N, Bauersachs RM, Anand SS, Patel MR, Fanelli F, Capell WH, Brackin T, Hinterreiter F, Krievins D, Nault P, Piffaretti G, Svetlikov A, Jaeger N, Hess CN, Sillesen HH, Conte M, Mills J, Muehlhofer E, Haskell LP, Berkowitz SD, Hiatt WR, Bonaca MP. Effect of Rivaroxaban and Aspirin in Patients With Peripheral Artery Disease Undergoing Surgical Revascularization: Insights From the VOYAGER PAD Trial. Circulation. 2021 10 05; 144(14):1104-1116.
Score: 0.198
-
Desai U, Kharat A, Hess CN, Milentijevic D, Lalibert? F, Zuckerman P, Benson J, Lefebvre P, Hiatt WR, Bonaca MP. Incidence of Major Atherothrombotic Vascular Events among Patients with Peripheral Artery Disease after Revascularization. Ann Vasc Surg. 2021 Aug; 75:217-226.
Score: 0.194
-
Desai U, Kharat A, Hess CN, Milentijevic D, Lalibert? F, Zuckerman P, Benson J, Lefebvre P, Hiatt WR, Bonaca MP. Healthcare resource utilization and costs of major atherothrombotic vascular events among patients with peripheral artery disease after revascularization. J Med Econ. 2021 Jan-Dec; 24(1):402-409.
Score: 0.190
-
Bonaca MP, Bauersachs RM, Anand SS, Debus ES, Nehler MR, Patel MR, Fanelli F, Capell WH, Diao L, Jaeger N, Hess CN, Pap AF, Kittelson JM, Gudz I, M?ty?s L, Krievins DK, Diaz R, Brodmann M, Muehlhofer E, Haskell LP, Berkowitz SD, Hiatt WR. Rivaroxaban in Peripheral Artery Disease after Revascularization. N Engl J Med. 2020 05 21; 382(21):1994-2004.
Score: 0.180
-
Bonaca MP, Hess CN, Hiatt WR. The Pathobiology of Acute Limb Ischemic?Events and Stent Failure in Peripheral Artery Disease: A Step in the Right Direction. JACC Cardiovasc Interv. 2020 02 24; 13(4):428-430.
Score: 0.179
-
Hiatt WR, Hess CN, Bonaca MP. Heterogeneity of Risk and Benefit in Subgroups of COMPASS: Relatively Similar But Absolutely Different. J Am Coll Cardiol. 2019 07 02; 73(25):3292-3294.
Score: 0.171
-
Rymer J, Anand SS, Sebastian Debus E, Haskell LP, Hess CN, Jones WS, Muehlhofer E, Berkowitz SD, Bauersachs RM, Bonaca MP, Patel MR. Rivaroxaban Plus Aspirin Versus Aspirin Alone After Endovascular Revascularization for Symptomatic PAD: Insights From VOYAGER PAD. Circulation. 2023 12 12; 148(24):1919-1928.
Score: 0.058
-
Secemsky EA, Barrette E, Bockstedt L, Bonaca MP, Hess CN, Hanson T, Monteiro J, Manda B, Yeh RW. Long-term safety of drug-coated devices for peripheral revascularisation. EuroIntervention. 2021 Sep 20; 17(7):590-598.
Score: 0.050
-
Hiatt WR, Hess CN, Bonaca MP, Kavanagh S, Patel MR, Baumgartner I, Berger JS, Blomster JI, Jones WS, Katona BG, Mahaffey KW, Norgren L, Rockhold FW, Fowkes FGR. Ankle-Brachial Index for Risk Stratification in Patients With Symptomatic Peripheral Artery Disease With and Without Prior Lower Extremity Revascularization: Observations From the EUCLID Trial. Circ Cardiovasc Interv. 2021 07; 14(7):e009871.
Score: 0.049
-
Bauersachs RM, Szarek M, Brodmann M, Gudz I, Debus ES, Nehler MR, Anand SS, Patel MR, Hess CN, Capell WH, Rogers K, Muehlhofer E, Haskell LP, Berkowitz SD, Hiatt WR, Bonaca MP. Total Ischemic Event Reduction With Rivaroxaban After Peripheral Arterial Revascularization in the VOYAGER PAD?Trial. J Am Coll Cardiol. 2021 07 27; 78(4):317-326.
Score: 0.049
-
Hiatt WR, Bonaca MP, Patel MR, Nehler MR, Debus ES, Anand SS, Capell WH, Brackin T, Jaeger N, Hess CN, Pap AF, Berkowitz SD, Muehlhofer E, Haskell L, Brasil D, Madaric J, Sillesen H, Szalay D, Bauersachs R. Rivaroxaban and Aspirin in Peripheral Artery Disease Lower Extremity Revascularization: Impact of Concomitant Clopidogrel on Efficacy and Safety. Circulation. 2020 12 08; 142(23):2219-2230.
Score: 0.047
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|